Cargando…

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various solid tumours including colorectal and glioblastomas. CD133 was found here to be highly expressed in ⩾50% of pancreatic, gastric and intrahepatic cholangiocarcinomas. Quantitative flow cytometric analysis showed that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, L M, Nesterova, A, Ryan, M C, Duniho, S, Jonas, M, Anderson, M, Zabinski, R F, Sutherland, M K, Gerber, H-P, Van Orden, K L, Moore, P A, Ruben, S M, Carter, P J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453027/ https://www.ncbi.nlm.nih.gov/pubmed/18542072 http://dx.doi.org/10.1038/sj.bjc.6604437

Ejemplares similares

Reply: CD133 expression in different stages of gastric adenocarcinoma
por: Smith, L M, et al.
Publicado: (2009)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
por: Oflazoglu, E, et al.
Publicado: (2009)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
por: Costa, F P, et al.
Publicado: (2011)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
por: Shen, B, et al.
Publicado: (2012)

Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway
por: Xie, C, et al.
Publicado: (2013)

Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts
por: Chiu, M, et al.
Publicado: (2014)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Biochemical and biological characterization of exosomes containing prominin-1/CD133
por: Rappa, Germana, et al.
Publicado: (2013)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells
por: Fan, S, et al.
Publicado: (2006)

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
por: Soh, C-L, et al.
Publicado: (2014)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells
por: Vaz, A P, et al.
Publicado: (2014)

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
por: Siveen, K S, et al.
Publicado: (2014)

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
por: Zlobec, I, et al.
Publicado: (2010)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma
por: Ding, Bi-Sen, et al.
Publicado: (2013)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

Effects of adiponectin on breast cancer cell growth and signaling
por: Grossmann, M E, et al.
Publicado: (2008)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
por: Someya, M, et al.
Publicado: (2011)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Altered TUBB3 expression contributes to the epothilone response of mitotic cells
por: Narvi, E, et al.
Publicado: (2013)

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57
por: Corazzari, M, et al.
Publicado: (2007)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nbpc1sqtkqiqg82snuku3s6eol